Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams

To participate in this activity, please:

An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity management.

In this 1-hour, online activity, lymphoma expert Jeremy Abramson, MD, shares his experience navigating these challenges as part of an interprofessional, multidisciplinary care team.

This activity is also available as a podcast: You may listen here

Course Credit:

1.00 AAPA Category I CME Credit
1.00 ACPE Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
1.00 Pharmacology Hour

Dates:

Opens: 2023-12-22
Closes: 2024-12-22

Target Audience:

This activity is developed to support hematologist-oncologists, hematology-oncology advanced practice providers, pathologists, and pharmacists who manage patients with follicular lymphoma.

This activity is supported by independent educational grants from Genentech, a member of the Roche Group, and Novartis Pharmaceuticals.

    Presenting Faculty

  • Jeremy S. Abramson, MD, MMSc

    Director, Lymphoma Program
    Jon and Jo Ann Hagler Chair in Lymphoma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts